This page has been robot translated, sorry for typos if any. Original content here.

Attention! The information is for reference only!
Before taking, be sure to consult a doctor!
SITE ONLY DIRECTORY. NOT A PHARMACY! We do not sell medicines! None!

Description of the medicine: Parmidin (Parmidinum)

PARMIDIN (Parmidinum).

Bis-N-methylcarbamic ester of 2, 6-bis-hydroxymethylpyridine, or 2, 6-pyridinyl-bis- (methyl-N-methylcarbamate).

Synonyms: Anginin, Pyridinol Carbamate, Prodectin, Acesterol, Andil, Anginin, Angiovital, Angioxine, Angioxyl, Aterofal, Aterokin, Atover, Cicloven, Colesterinex, Duaxol, Duvaline, Eluen, Exibral, Garparol, Katrombin, Prodectin, Prodectlin, Prodectin, Vasagin, Vasapril, Vasocil, Vasoverin, Veranterol, etc.

White or almost white crystalline powder. It is slightly soluble in water, it is difficult in alcohol.

Parmidin has angioprotective activity, reduces vascular permeability, and helps to restore impaired microcirculation during pathological processes. To a large extent, this is due to the effect on the kinin-kallikrein system, especially with a decrease in the activity of bradykinin. It also reduces platelet aggregation, stimulates fibrinogenesis.

Initially, parmidin (anginin) was proposed as an antisclerotic agent. As a bradykinin antagonist, it reduces the contraction of endothelial cells of arteries, as well as the gaps between them, and thus prevents the entry of atherogenic lipoproteins into the inner lining of blood vessels. With anti-inflammatory activity, parmidin also reduces endothelial cell edema, inhibiting lipid infiltration of the inner lining of blood vessels, and contributes to the reverse development of infiltrative changes in atherosclerosis. It also has moderate hypocholesterolemic activity.

Parmidin is not currently used as an independent antisclerotic agent, but it is widely used as a complex therapy in the treatment of atherosclerosis of the vessels of the brain, heart, extremities, atherosclerotic and diabetic angiopathy, retinal vein thrombosis, obliterating endarteritis, trophic ulcers of the extremities. The best effect was observed with lesions of peripheral vessels, especially vessels of the lower extremities, with diabetic angiopathies, mainly diabetic retinopathy. There is evidence of a positive effect of the drug on the state of the stomach and pancreas in diabetes mellitus, as well as the advisability of using parmidin (prodectin) in the complex treatment of patients with pulmonary tuberculosis. The drug accelerates the disappearance of intoxication symptoms and the resorption of infiltrates in the lungs. The tolerance of anti-TB chemotherapeutic drugs is improved.

It is advisable to combine parmidin with vitamins, enzymes, coenzymes, and, if necessary, with antidiabetic drugs (for diabetic angiopathies). There is a pronounced tendency to normalize lipid metabolism in chronic coronary artery disease when taking parmidine (prodectin) in combination with lipoic acid.

Parmidin is prescribed orally, starting with 0.25 g (1 tablet) 3-4 times a day. Then, with good tolerance, increase the dose to 0.75 g (3 tablets) 3-4 times a day. Typically, the daily dose is 1 to 2 g. The course of treatment is from 2 to 6 months or more.